• 1
    Walker AM. Confounding by indication. Epidemiology 1996; 7: 335336.
  • 2
    Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology 2009; 20: 512522.
  • 3
    Seeger JD, Walker AM, Williams PL, Saperia GM, Sacks FM. A propensity score-matched cohort study of the effect of statins, mainly fluvastatin, on the occurrence of acute myocardial infarction. Am J Cardiol 2003; 92: 14471451.
  • 4
    Cuzick J, Sestak I, Baum M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 2010; 11: 11351141.
  • 5
    Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003; 158: 915920.
  • 6
    Fetter RB, Shin Y, Freeman JL, Averill RF, Thompson JD. Case mix definition by diagnosis-related groups. Med Care 1980; 18: 153.
  • 7
    Dang DK, Pont JM, Portmoy MA. Episode treatment groups: an illness classification and episode building system--Part II. Med Interface 1996; 9: 122128.
  • 8
    Dang DK, Pont JM, Portnoy MA. Episode treatment groups: an illness classification and episode building system--Part I. Med Interface 1996; 9: 118122.
  • 9
    Forthman MT, Dove HG, Wooster LD. Episode Treatment Groups (ETGs): a patient classification system for measuring outcomes performance by episode of illness. Top Health Inf Manage 2000; 21: 5161.
  • 10
    Global Internet Management, U.S. Department of Commerce NTIS. Social Security Administration's Death Master File Database, 2011. [7 July 2011].
  • 11
    Eng PM, Seeger JD, Loughlin J, Clifford CR, Mentor S, Walker AM. Supplementary data collection with case-cohort analysis to address potential confounding in a cohort study of thromboembolism in oral contraceptive initiators matched on claims-based propensity scores. Pharmacoepidemiol Drug Saf 2008; 17: 297305.
  • 12
    Walker AM. Observation and inference: an introduction to the methods of epidemiology. Epidemiology Resources Inc.: Chestnut Hill, MA, 1991.
  • 13
    Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf 2006; 15: 291303.
  • 14
    US Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2010. [8 July 2011].
  • 15
    Dore DD, Bloomgren GL, Wenten M, et al. A cohort study of acute pancreatitis in relation to exenatide use. Diabetes Obes Metab 2011; 13: 559566. DOI: 10.1111/j.1463-1326.2011.01376.x.
  • 16
    Schneeweiss S, Glynn RJ, Tsai EH, Avorn J, Solomon DH. Adjusting for unmeasured confounders in pharmacoepidemiologic claims data using external information: the example of COX2 inhibitors and myocardial infarction. Epidemiology 2005; 16: 1724.
  • 17
    Sturmer T, Glynn RJ, Rothman KJ, Avorn J, Schneeweiss S. Adjustments for unmeasured confounders in pharmacoepidemiologic database studies using external information. Med Care 2007; 45: S158S165.
  • 18
    Sturmer T, Schneeweiss S, Rothman KJ, Avorn J, Glynn RJ. Propensity Score Calibration and its Alternatives. Am J Epidemiol 2007; 165: 11221123.
  • 19
    Sturmer T, Schneeweiss S, Rothman KJ, Avorn J, Glynn RJ. Performance of propensity score calibration--a simulation study. Am J Epidemiol 2007; 165: 11101118.
  • 20
    Walker AM. Anamorphic analysis: sampling and estimation for covariate effects when both exposure and disease are known. Biometrics 1982; 38: 10251032.
  • 21
    Lash TL. Heuristic thinking and inference from observational epidemiology. Epidemiology 2007; 18: 6772.
  • 22
    Sturmer T, Schneeweiss S, Avorn J, Glynn RJ. Adjusting effect estimates for unmeasured confounding with validation data using propensity score calibration. Am J Epidemiol 2005; 162: 279289.
  • 23
    Fowler FJ. Survey research methods (3rd edn). Sage Publications: Thousand Oaks, CA, 2002.
  • 24
    McKenzie DA, Semradek J, McFarland BH, Mullooly JP, McCamant LE. The validity of medicaid pharmacy claims for estimating drug use among elderly nursing home residents: The Oregon experience. J Clin Epidemiol 2000; 53: 12481257.
  • 25
    Rothman KJ, Greenland S, Lash TL. Modern epidemiology (3rd edn). Wolters Kluwer Health/Lippincott Williams & Wilkins: Philadelphia, 2008.
  • 26
    Dore DD, McAfee AT, Woo RK, Seeger JD. Enhanced Oncology Applications of Health Insurance Claims Data through Clinical Data Linkage (Abstract 081). Pharmacoepidemiol Drug Saf 2009; 18: S36. DOI: 10.1002/pds.2206.